MX2014010713A - Activacion de procaspasa 3 mediante terapia de combinacion. - Google Patents

Activacion de procaspasa 3 mediante terapia de combinacion.

Info

Publication number
MX2014010713A
MX2014010713A MX2014010713A MX2014010713A MX2014010713A MX 2014010713 A MX2014010713 A MX 2014010713A MX 2014010713 A MX2014010713 A MX 2014010713A MX 2014010713 A MX2014010713 A MX 2014010713A MX 2014010713 A MX2014010713 A MX 2014010713A
Authority
MX
Mexico
Prior art keywords
compounds
procaspase
activation
combination therapy
combinations
Prior art date
Application number
MX2014010713A
Other languages
English (en)
Other versions
MX359210B (es
Inventor
Paul J Hergenrother
Rachel C Botham
Timothy M Fan
Mark J Gilbert
Michael K Handley
Howard S Roth
Theodore M Tarasow
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of MX2014010713A publication Critical patent/MX2014010713A/es
Publication of MX359210B publication Critical patent/MX359210B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona composiciones y métodos para la inducción de muerte celular, por ejemplo, muerte de células de cáncer. Las combinaciones de compuestos y métodos relacionados de uso son descritos, incluyendo el uso de compuestos en terapia para el tratamiento de cáncer e inducción selectiva de apoptosis en células. Las combinaciones de medicamentos descritas pueden tener menores efectos de neurotoxicidad que otros compuestos y combinaciones de compuestos.
MX2014010713A 2012-03-06 2013-03-06 Composición de combinación de pac-1 y tamoxifeno. MX359210B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607098P 2012-03-06 2012-03-06
PCT/US2013/029405 WO2013134407A2 (en) 2012-03-06 2013-03-06 Procaspase 3 activation by combination therapy

Publications (2)

Publication Number Publication Date
MX2014010713A true MX2014010713A (es) 2015-03-10
MX359210B MX359210B (es) 2018-09-19

Family

ID=49117502

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014010713A MX359210B (es) 2012-03-06 2013-03-06 Composición de combinación de pac-1 y tamoxifeno.
MX2017013045A MX365392B (es) 2012-03-06 2013-03-06 Composición de combinación de pac-1 y doxorrubicina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017013045A MX365392B (es) 2012-03-06 2013-03-06 Composición de combinación de pac-1 y doxorrubicina.

Country Status (15)

Country Link
US (4) US9399035B2 (es)
EP (2) EP2822558B1 (es)
JP (1) JP6172865B2 (es)
KR (1) KR102074530B1 (es)
CN (1) CN104507479B (es)
AU (1) AU2016213862B2 (es)
BR (1) BR112014022103B1 (es)
CA (1) CA2866021C (es)
DK (1) DK2822558T3 (es)
ES (1) ES2774930T3 (es)
HK (1) HK1204984A1 (es)
IN (1) IN2014MN01945A (es)
MX (2) MX359210B (es)
RU (1) RU2659936C2 (es)
WO (2) WO2013134407A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
MX359210B (es) * 2012-03-06 2018-09-19 Univ Illinois Composición de combinación de pac-1 y tamoxifeno.
NZ716765A (en) * 2013-11-01 2020-02-28 Pitney Pharmaceuticals Pty Ltd Pharmaceutical combinations for the treatment of cancer
JP2017538699A (ja) 2014-12-05 2017-12-28 エーエヌ２エイチ ディスカバリー リミテッド パーキンリガーゼ活性化の方法及び組成物
US10350207B2 (en) 2015-06-05 2019-07-16 The Board Of Trustees Of The University Of Illinois PAC-1 combination therapy
KR101712638B1 (ko) * 2015-08-19 2017-03-07 한국과학기술연구원 Pac-1을 이용한 단백질 발현 조절 시스템과 방법 및 pac-1을 유효성분 포함하는 독시사이클린 길항제
EP3463347A4 (en) 2016-06-03 2019-12-18 An2H Discovery Limited TRIAZOLBENZAMID DERIVATIVES AND COMPOSITIONS AND METHODS FOR TREATMENT RELATED TO THIS
CN111491927A (zh) * 2017-11-17 2020-08-04 伊利诺伊大学董事会 通过降解双mek信号传导的癌症疗法
US10889553B2 (en) 2017-12-01 2021-01-12 Nysnobio Ireland Dac Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same
EP3852744A4 (en) * 2018-10-05 2022-06-08 The Board of Trustees of the University of Illinois COMBINATION THERAPY FOR THE TREATMENT OF CHOROID MELANOMA
US20220226311A1 (en) * 2019-05-30 2022-07-21 The Board Of Trustees Of The University Of Illinois Procaspase-3 activation and immunotherapy for treatment of cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US597287A (en) 1898-01-11 Bicycle attachment
US5723459A (en) * 1991-05-09 1998-03-03 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US5844001A (en) * 1993-02-26 1998-12-01 Research Development Foundation Combination platinum chemotherapeutic/antiestrogen therapy for human cancers
US6403765B1 (en) 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
AU5205499A (en) 1998-07-27 2000-02-21 Pharmacia & Upjohn Company Method for autoactivation of procaspase 8
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002030399A2 (en) 2000-10-11 2002-04-18 Johns Hopkins University Polymer controlled delivery of a therapeutic agent
AU2002241508A1 (en) 2000-11-20 2002-06-24 Lawrence C. Fritz Membrane derived caspase-3, compositions comprising the same and methods of use therefor
DE10128840A1 (de) * 2001-06-15 2003-01-09 Otis Elevator Co Verfahren und Vorrichtung zur Steuerung des Antriebs einer Fördereinrichtung
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
US6702122B2 (en) * 2002-07-11 2004-03-09 Frank G. Hopkins Rack for fork lift extensions
US20040180828A1 (en) 2003-01-30 2004-09-16 Yigong Shi Caspase-9 : BIR domain of XIAP complexes and methods of use
US7632972B2 (en) 2003-10-30 2009-12-15 The Board Of Trustees Of The University Of Illionis Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
DE602004024115D1 (de) * 2003-12-09 2009-12-24 Us Gov Health & Human Serv Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
US20080193448A1 (en) * 2005-05-12 2008-08-14 Pfizer Inc. Combinations and Methods of Using an Indolinone Compound
US20070049602A1 (en) * 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
CN101184491A (zh) * 2005-05-26 2008-05-21 伊利诺伊大学评议会 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导
US8207186B2 (en) 2005-06-23 2012-06-26 Merck Sharp & Dohme Corp. Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase MET
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
CN101304743B (zh) * 2005-09-19 2012-09-05 诺伊罗纳森特公司 刺激神经形成和抑制神经元变性的方法和组合物
PE20071042A1 (es) * 2005-11-04 2007-10-12 Wyeth Corp Producto farmaceutico que comprende temsirolimus y malato de sunitinib
US20070111936A1 (en) 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
US7886969B2 (en) 2005-12-06 2011-02-15 Visa U.S.A. Inc. Method and system for loading and reloading portable consumer devices
US8778845B2 (en) * 2005-12-15 2014-07-15 Genral Electric Company Composition, device and associated method
JP2009537636A (ja) 2006-05-19 2009-10-29 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ 黒色腫及び他の癌を治療するためのトリフェニルメチルホスホン酸エステルを含めたリン含有化合物
TWI433674B (zh) * 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2009076170A2 (en) * 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
RU2360692C1 (ru) * 2007-12-21 2009-07-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, стимулирующее апоптоз клеток лейкемии человека
EP2237784A1 (en) 2008-01-11 2010-10-13 The Regents of the University of California Activators of executioner procaspases 3, 6 and 7
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
KR101213166B1 (ko) * 2008-09-17 2012-12-18 가부시키가이샤 어드밴티스트 시험 장치 및 도메인간 동기 방법
US20100291214A1 (en) 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8778945B2 (en) 2009-02-09 2014-07-15 The Board Of Trustees Of The University Of Illinois Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs
EA201101519A1 (ru) 2009-05-11 2012-10-30 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
CA2763471A1 (en) * 2009-05-27 2010-12-02 Cephalon, Inc. Combination therapy for the treatment of multiple myeloma
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
JP5094797B2 (ja) 2009-08-07 2012-12-12 日立オートモティブシステムズ株式会社 直流電源平滑用コンデンサーの放電回路
CN102085214A (zh) * 2011-01-27 2011-06-08 范晓青 低分子柑橘果胶联和临床常用化疗药用于控制癌症和癌症转移扩散
MX359210B (es) * 2012-03-06 2018-09-19 Univ Illinois Composición de combinación de pac-1 y tamoxifeno.
US10350207B2 (en) * 2015-06-05 2019-07-16 The Board Of Trustees Of The University Of Illinois PAC-1 combination therapy

Also Published As

Publication number Publication date
CN104507479A (zh) 2015-04-08
EP4274558A1 (en) 2023-11-15
JP6172865B2 (ja) 2017-08-02
US20190099418A1 (en) 2019-04-04
AU2016213862B2 (en) 2018-08-23
RU2659936C2 (ru) 2018-07-04
US20210128551A1 (en) 2021-05-06
JP2015509965A (ja) 2015-04-02
US20150017264A1 (en) 2015-01-15
IN2014MN01945A (es) 2015-07-10
MX359210B (es) 2018-09-19
CA2866021A1 (en) 2013-09-12
US20160346277A1 (en) 2016-12-01
MX365392B (es) 2019-05-31
US10085977B2 (en) 2018-10-02
KR20140143166A (ko) 2014-12-15
CA2866021C (en) 2020-09-22
CN104507479B (zh) 2017-08-18
EP2822558A2 (en) 2015-01-14
RU2014139954A (ru) 2016-04-27
HK1204984A1 (en) 2015-12-11
US11833147B2 (en) 2023-12-05
AU2013230994A1 (en) 2014-10-16
US10888560B2 (en) 2021-01-12
DK2822558T3 (da) 2020-03-23
AU2016213862A1 (en) 2016-09-01
BR112014022103B1 (pt) 2022-04-19
WO2022150633A1 (en) 2022-07-14
WO2013134407A2 (en) 2013-09-12
EP2822558B1 (en) 2020-02-19
KR102074530B1 (ko) 2020-02-06
EP2822558A4 (en) 2015-08-05
WO2013134407A3 (en) 2013-10-24
ES2774930T3 (es) 2020-07-23
BR112014022103A2 (es) 2017-08-22
US9399035B2 (en) 2016-07-26

Similar Documents

Publication Publication Date Title
MX2014010713A (es) Activacion de procaspasa 3 mediante terapia de combinacion.
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2021001878A (es) Metodos y composiciones para mejorar las celulas t reguladoras cd4+.
MY187540A (en) Compounds active towards bromodomains
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
GB201106750D0 (en) Novel compounds
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
MX2016008448A (es) Conjugados de var2csa-farmaco.
GB201209613D0 (en) New compounds
GB201106743D0 (en) Novel compounds
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
PH12015501088A1 (en) Dimeric compounds
MX364002B (es) Compuestos y composiciones activadoras de enzima.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2019015527A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
WO2013131089A3 (en) Potent anticancer activity via dual compound activation
MX2017015532A (es) Terapia de combinacion pac-1.
MX359209B (es) Terapia de combinacion de procaspasa para gliobastoma.
JO3630B1 (ar) توليفة أليسيرتيب وباكليتاكسيل لعلاج السرطان
GB2528604A (en) Modulation of asymmetric proliferation
MX350868B (es) Medicamentos y metodos para tratar cancer.

Legal Events

Date Code Title Description
FG Grant or registration